Skip to content

Released Nov 10, 2026, before the open

10-Q filed Nov 10, 2026, 41 days after period end · 0001104659-26-124771

Q3 2026 · 10-Q
Revenue$21.93M+22.8% vs Q3 2025+10.2% vs Q2 2026
Net Income$3.96M+68.2% vs Q3 2025+4.9% vs Q2 2026
EPS Diluted$0.05+66.7% vs Q3 2025±0.0% vs Q2 2026
Operating Income$4,047,000+89.9%
Operating Cash Flowderived$3,904,000N/M
Free Cash Flowderived$3,167,000N/M
Margins · derived
Operating margin18.5%+6.5 pt vs Q3 2025
Net margin18.1%+4.9 pt vs Q3 2025

What the release said

Net income for the three months ended September 30, 2026 was $4.0 million, or $0.05 per share, basic and diluted, compared to $2.4 million, or $0.03 per share, basic and diluted, for the same period in 2025.

Total revenues increased by $32.0 million year to date to $75.6 million, from $43.6 million for the same period in 2025.2

Net income for the third quarter was $4.0 million, or $0.05 per share, basic and diluted, compared with $2.4 million, or $0.03 per share, a year earlier.1

Net income for the nine months ended September 30, 2026 was $26.1 million, or $0.33 per share, basic, and $0.31 per share, diluted.1

The company reaffirmed 2026 total revenue guidance of approximately $78.0 million to $83.0 million, including a $25.0 million milestone payment from Chiesi in Q1 2026.23

Cash, cash equivalents, and short-term bank deposits were $48.5 million at September 30, 2026.4

Total revenues, nine months 2026
$75.6 million Nine months ended September 30, 2026, increased by $32.0 million year to date from $43.6 million for the same period in 20252
Net income, third quarter 2026
$4.0 million Three months ended September 30, 2026, $0.05 per share, basic and diluted, compared to $2.4 million, or $0.03 per share, for the same period in 20251
Net income, nine months 2026
$26.1 million Nine months ended September 30, 2026, $0.33 per share basic and $0.31 per share diluted, compared to a net loss of $1.1 million for the same period in 20251
2026 total revenue guidance
approximately $78.0 million to $83.0 million Reaffirmed; management expects to meet or exceed this range, including a $25.0 million Chiesi milestone received in Q1 20263
Cash, cash equivalents and short-term bank deposits
$48.5 million As of September 30, 20264
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$21.93M$17.85M$17.96M$10.35M
Net Income$3.96M$2.36M$3.24M-$1.85M
EPS Diluted$0.05$0.03$0.03-$0.04

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR